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Once again, our colleagues from Paul Brousse Hospital1 must be
congratulated for the experience they have accrued and, more
importantly, for providing relevant evidence to the surgical com-
munity, albeit that the number of patients they report is small.
This current article focuses on the extreme situation in which the
liver parenchyma is left with no arterial supply following a surgical
procedure. Unless oxygen is provided to the liver, the outcome is
likely to be dismal.
To overcome this challenge, the authors1 suggest performing
portal vein arterialization (PVA) and present the results of the
largest number of patients with the longest follow-up reported to
date. They also discuss an extensive literature review.1
The expectation is that emergency re-arterialization of the liver
will allow the organ, including not only hepatocytes but also, and
in particular, the biliary tree, to survive while the body develops
arterial collaterals. The results emerging from this combined
group of transplant and hepatic resection patients are exceptional:
the authors report an overall survival rate of 63% at a median
follow-up of 13 months.1
A number of factors should be considered in order to facilitate
better understanding of the impact of PVA. The authors1 describe
each case precisely and the reader should reflect on the detail. In
the selected group of patients who underwent hepatic resection,
PVA either extended the possibility of negative margin (R0) resec-
tion or rescued an extremely serious situation in which the hepatic
artery had been injured or lost. In the latter context of an
unplanned interruption of the hepatic artery, there was simply no
alternative. Of the seven transplant recipients, three suffered a
graft loss, one of whom died. The benefits to be derived from PVA
in patients with acute hepatic artery thrombosis (HAT) are more
debatable because an alternative strategy, namely the standard of
care, retransplantation, is available. However, clearly this option is
dependent upon access to a super-urgent or priority registration.
If the outcome on intention to treat after listing is poor, such as
might result from a low donation rate or an unsatisfactory super-
urgent registration scheme, PVA might well be considered as an
alternative strategy or even as a bridge to a more elective surgical
scenario, as the paper implies.1
The authors1 suggest that mortality following retransplantation
for HAT may reach 50%, but this statistic does not reflect current
data; recent large reviews,2 such as that from the University of
California Los Angeles, report better outcomes. In addition, the
likelihood of the successful salvage of a graft should be balanced
against the very probably already established ischaemic biliopathy,
particularly in patients with late HAT presenting with sepsis or
bilomas.
Morbidity following PVA has been high, but this should be
considered in the context of the natural course of events in a
de-arterialized liver. Following PVA, up to 44% of patients
experienced complications resulting from portal hypertension,
although only three patients required invasive treatment and two
ultimately died.1 On four occasions the PVA shunt was affected
by thrombosis, but intervention was required in only two of
these patients, one of whom underwent repeat surgery and
subsequently died and one of whom underwent repeat liver
transplantation.1
The authors1 provide extremely valuable information on their
technique of choice when PVA is considered and address the issue
of longterm management. Ideally, PVA should be interrupted in
an elective manner to minimize the consequences of an
arterialized portal vein.
The role of PVA remains uncertain, particularly within the
transplant setting. A great deal of information is made available to
enable individual surgeons to determine where to position this
technique in their practice. There is no doubt that PVA should
be considered as part of the surgical armamentarium in
hepatopancreatobiliary and liver transplant surgery, but its careful
application is essential. It is not for the faint-hearted.
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